

jc595 U.S. PTO
06/18/99

Patent
Attorney's Docket No. 012712-696

jc490 U.S. PTO
09/335686
06/18/99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

REQUEST FOR FILING CONTINUATION/DIVISIONAL
APPLICATION UNDER 37 C.F.R. § 1.53(b)

Box PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This is a request for filing a ☐ continuation ☒ divisional application under 37 C.F.R. § 1.53(b) of pending Application No. 08/475,873 filed on June 7, 1995, for METHOD FOR PROLONGED SUPPRESSION OF HUMORAL IMMUNE RESPONSE TO A THYMUS-DEPENDENT ANTIGEN THERAPEUTIC AGENT, by the following named inventor(s):

- (a) Full Name Randolph J. NOELLE
(b) Full Name Teresa M. FOY
(c) Full Name _____

☒ The entire disclosure of the prior application from which a copy of the oath or declaration is supplied herewith is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

☐ This application is being filed by less than all the inventors named in the prior application. In accordance with 37 C.F.R. 1.63(d)(2), the Commissioner is requested to delete the name(s) of the following person or persons who are not inventors of the invention being claimed in this application.

- (a) Full Name _____
(b) Full Name _____
(c) Full Name _____

1. ☒ Enclosed is a copy of the prior Application No. 08/475,873 as originally filed on June 7, 1995, including copies of the specification, claims, drawings and the executed oath or declaration as filed.
2. ☐ Enclosed is a revised prior application and a copy of the prior executed oath or declaration as filed. No new matter has been added to the revised application.
3. ☒ One statement(s) claiming small entity status ☐ are enclosed ☒ were filed in prior Application No. 08/475,873, filed on June 7, 1995.

4. ☒ The filing fee is calculated below ☐ and in accordance with the enclosed preliminary amendment:


CLAIMS					
	NO. OF CLAIMS		EXTRA CLAIMS	RATE	FEE
Basic Application Fee					\$760.00
Total Claims	1	MINUS 20 =	0	x \$18.00 =	0.00
Independent Claims	1	MINUS 3 =	0	x \$78.00 =	0.00
If multiple dependent claims are presented, add \$260.00					0.00
Total Application Fee					760.00
If small entity status is claimed, subtract 50% of Total Application Fee					380.00
Add Assignment Recording Fee of \$40.00 if Assignment document is enclosed					0.00
TOTAL APPLICATION FEE DUE					380.00

5. ☐ Charge \$ _____ to Deposit Account No. 02-4800 for the fee due.
6. ☒ A check in the amount of \$ 380.00 is enclosed for the fee due.
7. ☒ The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in triplicate.
8. ☒ Cancel in this application original claims 2-43 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
9. ☒ Amend the specification by inserting before the first line the sentence: --This application is a ☐ continuation, ☒ divisional, of Application No. 08/475,873, filed June 7, 1995; which in turn is a continuation of 08/111,990, filed September 2, 1993.--
10. ☐ Transfer the drawings from the pending prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate of this paper is enclosed for filing in the prior application file. (May only be used if signed by person authorized under 37 C.F.R. § 1.138 and before payment of issue fee.)

11. ☒ New drawings are enclosed.
12. ☐ Priority of Application No. ___ filed on ___ in ___ (country) is claimed under 35 U.S.C. § 119.
- ☐ The certified copy of the priority application
- ☐ is enclosed
 - ☐ was filed on ___ in prior Application No. ___, filed on ___
 - ☐ has not yet been filed.
13. ☒ A preliminary amendment is enclosed.
14. ☒ Also enclosed Request for Listing of References Considered by Examiner w/PTO-1449s.
15. ☒ The power of attorney in the prior application is to E. Joseph Gess.
- a. ☒ The power appears in the original papers in the prior application.
 - b. ☐ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
 - c. ☒ Recognize as Associate Attorney Robin L. Teskin, Reg. No. 35,030.
 - d. ☒ Address all future communications to: (May only be completed by applicant, or attorney or agent of record.)

E. Joseph Gess
BURNS, DOANE, SWECKER & MATHIS, L.L.P.
P.O. Box 1404
Alexandria, Virginia 22313-1404

June 18, 1999
Date

By: 
Robin L. Teskin
Registration No. 35,030

ADDRESS OF
SIGNATOR:

BURNS, DOANE, SWECKER & MATHIS, L.L.P.
P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

☐ inventor(s)
☐ assignee of complete interest
☐ attorney or agent of record
☒ filed under 37 C.F.R. § 1.34(a)

COPY

Applicant or Patentee: Randolph J. Noelle and Teresa M. Foy
Serial or Patent No.: 08/475,873
Filed or Issued: June 7, 1995
Title: METHODS OF PROLONGED SUPPRESSION OF HUMORAL IMMUNITY

Attorney's
Docket No.: DCI-073CN

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(d)) - NONPROFIT ORGANIZATION

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF NONPROFIT ORGANIZATION Trustees of Dartmouth College
ADDRESS OF NONPROFIT ORGANIZATION Hanover, NH 03755
TYPE OF NONPROFIT ORGANIZATION
☒ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
☐ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) and 501(c)(3))
☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)
☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) and 501(c)(3)) IF LOCATED IN THE UNITED STATES OF AMERICA
☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention entitled
METHODS OF PROLONGED SUPPRESSION OF HUMORAL IMMUNITY

by inventor(s) Randolph J. Noelle and Teresa M. Foy
described in
☐ the specification filed herewith.
☒ application serial no. 08/475,873, filed June 7, 1995
☐ patent no. _____, issued _____

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization regarding the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights in the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

NAME _____
ADDRESS _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING John F. Kavanagh, Ph.D.
TITLE IN ORGANIZATION OF PERSON SIGNING Director, Office of Grants and Contracts
ADDRESS OF PERSON SIGNING Dartmouth College, 6210 Raven House, Hanover, NH 03755

SIGNATURE

DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
)
Randolph J. NOELLE et al.) Group Art Unit: Unassigned
)
Application No. Unassigned) Examiner: Unassigned
)
Filed: June 18, 1999)
)
For: METHOD FOR PROLONGED)
SUPPRESSION OF HUMORAL)
IMMUNE RESPONSE TO A)
THYMUS-DEPENDENT ANTIGEN)
THERAPEUTIC AGENT)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination, please first amend the above-identified application as follows:

IN THE SPECIFICATION

Delete the Title and substitute the following therefor: --METHOD FOR PROLONGED SUPPRESSION OF HUMORAL IMMUNE RESPONSE TO A THYMUS-DEPENDENT ANTIGEN THERAPEUTIC AGENT--.

Page 9, line 5, change "Balb/c" to --BALB/C--.


Page 16, lines 30, change "Balb/c" to --BALB/C--.

REMARKS

These amendments are made to expedite prosecution. Favorable consideration on the merits is respectfully requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Robin L. Teskin
Registration No. 35,030

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: June 18, 1999

METHODS OF PROLONGED SUPPRESSION OF HUMORAL IMMUNITY

Government Funding

The work leading to this invention may have been supported by one or more grants from the U.S. government. The U.S. government therefore may have certain rights in this invention.

Background of the Invention

The immune system is capable of producing two types of antigen-specific responses to foreign antigen. Cell-mediated immunity is the term used to refer to effector functions of the immune system mediated by T lymphocytes. Humoral immunity is the term used to refer to production of antigen-specific antibodies by B lymphocytes. It has long been appreciated that the development of humoral immunity against most antigens requires not only antibody-producing B lymphocytes but also the involvement of helper T (hereafter Th) lymphocytes. Mitchison, *Eur. J. Immunol.*, 1:18-25 (1971); Claman and Chaperon, *Transplant Rev.*, 1:92-119 (1969); Katz et al., *Proc. Natl. Acad. Sci. USA*, 70:2624-2629 (1973); Raff et al., *Nature*, 226:1257-1260 (1970). Certain signals, or "help", are provided by Th cells in response to stimulation by thymus-dependent (hereafter TD) antigens. While some B lymphocyte help is mediated by soluble molecules released by Th cells (for instance lymphokines such as IL-4 and IL-5), activation of B cells also requires a contact-dependent interaction between B cells and Th cells. Hirohata et al., *J. Immunol.*, 140:3736-3744 (1988); Bartlett et al., *J. Immunol.*, 143:1745-1754 (1989). This indicates that B cell activation involves an obligatory interaction between cell surface molecules on B cells and Th cells. Such an interaction is further supported by the observation that isolated plasma membranes of activated T cells can provide helper functions necessary for B cell activation. Brian, *Proc. Natl. Acad. Sci. USA*, 85:564-568 (1988); Hodgkin et al., *J. Immunol.*, 145:2025-2034 (1990); Noelle et al., *J. Immunol.*, 146:1118-1124 (1991).

003566 061899 668790 98956660

A cell surface molecule, CD40, has been identified on immature and mature B lymphocytes which, when crosslinked by antibodies, induces B cell proliferation. Valle et al., *Eur. J. Immunol.*, 19:1463-1467 (1989); Gordon et al., *J. Immunol.*, 140:1425-1430 (1988); Gruber et al., *J. Immunol.*, 142: 4144-4152 (1989). CD40 has been molecularly cloned and characterized. Stamenkovic et al., *EMBO J.*, 8:1403-1410 (1989). A ligand for CD40, gp39 (also called CD40 ligand or CD40L) has also been molecularly cloned and characterized. Armitage et al., *Nature*, 357:80-82 (1992); Lederman et al., *J. Exp. Med.*, 175:1091-1101 (1992); Hollenbaugh et al., *EMBO J.*, 11:4313-4319 (1992). The gp39 protein is expressed on activated, but not resting, CD4⁺ Th cells. Spriggs et al., *J. Exp. Med.*, 176:1543-1550 (1992); Lane et al., *Eur. J. Immunol.*, 22:2573-2578 (1992); Roy et al., *J. Immunol.*, 151:1-14 (1993). Cells transfected with the gp39 gene and expressing the gp39 protein on their surface can trigger B cell proliferation and, together with other stimulatory signals, can induce antibody production. Armitage et al., *Nature*, 357:80-82 (1992); Hollenbaugh et al., *EMBO J.*, 11:4313-4319 (1992).

While the induction of a humoral immune response is an important host defense mechanism, in certain situations it would be beneficial to suppress antibody production against a particular antigen. For example, suppression of a humoral response against an allergen could prevent or reduce an allergic response in an individual. Additionally, when a therapeutic antibody is administered, suppressing a humoral response against the antibody could prolong the therapeutic efficacy of the antibody.

Summary of the Invention

One approach to suppressing humoral immunity is to inhibit B cell activation. The current invention pertains to methods for inhibiting a humoral immune response to a TD antigen *in vivo* by inhibiting the ability of a Th cell to stimulate a B cell, thereby interfering with B cell activation and antibody production. The invention is based, at least in part, on the necessity for an *in vivo* interaction between gp39 on a Th cell and CD40 on a B cell for subsequent activation of the B cell. Antagonists of gp39, which are effective for inhibiting the interaction of gp39 with CD40 *in vivo*, are administered to a subject together with a TD antigen to suppress humoral immunity against the

0933566, 061899
668790" 98957660

TD antigen. The gp39 antagonist which is administered can be an antibody directed against gp39. In a preferred embodiment, the gp39 antagonist is a monoclonal antibody, such as a anti-human gp39 antibody or an anti-mouse gp39 antibody (e.g., MR1). Chimeric antibodies, humanized antibodies and antibody fragments are also within the scope of the invention. Alternatively, the gp39 antagonist can be a soluble form of the gp39 ligand CD40. Soluble fusion proteins of CD40 are also encompassed by the invention.

The humoral immune response inhibited by the methods of the current invention can be a primary humoral immune response, in the case of initial exposure to an antigen, or a secondary humoral immune response, in the case of reexposure to a previously encountered antigen. For example, the methods described herein can be used to inhibit production of antigen-specific IgM antibodies, IgG antibodies, IgD antibodies and/or IgE antibodies. In addition, the methods provide for prolonged suppression of humoral immune responses *in vivo*.

One aspect of the invention provides methods for inhibiting humoral immune responses to TD antigens. Antigens embraced by the invention include antigens for which specific antibody production requires interaction of gp39 with a ligand on the surface of B cells (e.g., CD40). TD antigens generally include proteinaceous antigens. In preferred embodiments of the invention, the antigen is a therapeutic antibody, drug, allergen or foreign cell. The methods of the present invention also are effective for inhibiting humoral immune responses to a TD antigen while preserving humoral immune responses to thymus-independent type II (hereafter TI-2) antigens.

Another aspect of the invention pertains to methods for specifically inhibiting the helper function of activated Th cells *in vivo* by interfering with the interaction of gp39 with a ligand on the surface of B cells (e.g., CD40) by administering a gp39 antagonist. According to this method, helper function of activated Th cells is inhibited *in vivo* without deleting or anergizing Th cells.

The invention further pertains to methods of inhibiting humoral immune responses *in vivo* by a combined administration of a gp39 antagonist and another immunosuppressive agent. Other immunosuppressive agents which can be provided in conjunction with a gp39 antagonist include

cytokine inhibitors, inhibitors of the CD28/CTLA4 T cell costimulatory pathway, or immunosuppressive drugs.

A still further aspect of the present invention is a method for determining whether an antigen is a TD or TI-2 antigen. This can be determined by whether or not humoral immune responses to the antigen *in vivo* can be inhibited by administration of a gp39 antagonist.

Brief Description of the Drawings

Figure 1A is a bar graph depicting suppression of primary anti-SRBC IgM antibody production by *in vivo* anti-gp39 treatment.

Figure 1B is a graph depicting prolonged suppression of primary anti-SRBC IgM antibody production after short-term *in vivo* anti-gp39 treatment.

Figure 2A is a bar graph depicting suppression of secondary anti-KLH antibody production (various isotypes) by *in vivo* anti-gp39 treatment. Antibody titers were measured 7 days after antigen challenge.

Figure 2B is a bar graph depicting suppression of secondary anti-KLH antibody production (various isotypes) by *in vivo* anti-gp39 treatment. Antibody titers were measured 14 days after antigen challenge.

Figure 3 is two bar graphs depicting suppression of primary anti-ChiL6 IgM antibody production (left) and secondary anti-ChiL6 IgG1 antibody production (right) by *in vivo* anti-gp39 treatment.

Figure 4A is a bar graph depicting suppression of primary anti-TNP IgM antibody production by immunization with TNP-SRBC and *in vivo* anti-gp39 treatment.

Figure 4B is a bar graph depicting lack of suppression of primary anti-TNP IgM antibody production by immunization with TNP-Ficoll and *in vivo* anti-gp39 treatment.

Figure 5 is a bar graph depicting intact helper activity of T cells previously exposed to anti-gp39 treatment *in vivo* upon adoptive transfer to untreated mice, demonstrating that anti-gp39 administration does not functionally delete Th cells.

Figure 6A is a Western blot depicting anti-gp39 antibody present in serum 7, 14 and 21 days after *in vivo* administration.

Figure 6B is a graph depicting percent of remaining anti-gp39 activity in serum 7, 14 and 21 days after *in vivo* administration.

Detailed Description of the Invention

The generation of humoral immunity to thymus-dependent (TD) antigens requires not only B lymphocytes, which can produce specific antibodies against an antigen, but also contributions from Th cells which are necessary for activation of B lymphocytes. Although T helper cell function does involve production of cytokines utilized by B lymphocytes, the Th cell requirement for B cell activation cannot be eliminated by providing exogenous cytokines to B cells. Rather, a contact-dependent, cell membrane-mediated interaction between B cells and Th cells is integral to induction of humoral responses. A receptor-ligand pair involved in this interaction, CD40 and gp39, has been identified. CD40 is present on B cells and has the ability to bind to gp39, which is induced on Th cells upon activation, leading to stimulation of the B cells and ultimately production of specific antibodies. Disruption of the CD40-gp39 interaction offers a means of interfering with the generation of a specific humoral immune response.

Accordingly, this invention pertains to methods of inhibiting humoral immune responses against a TD antigen *in vivo*. Humoral immune responses are inhibited by interfering with the interaction of a molecule on a Th cell which mediates contact-dependent helper effector function and its ligand on the surface of a B lymphocyte. In a preferred embodiment, humoral immune responses are inhibited by interfering with the interaction of gp39 on a T cell and CD40 on a B cell exposed to the TD antigen through administration of a gp39 antagonist to a subject *in vivo*. In one embodiment, the B cell is exposed to the TD antigen by administration of the antigen *in vivo* with the gp39 antagonist. Preferably, this TD antigen is a therapeutic agent, for example a therapeutic antibody or drug, which is administered to the patient for therapeutic treatment and for which inhibiting humoral immune responses against it can result in prolonged therapeutic efficacy of the agent. In another embodiment, the TD antigen is an antigen to which a subject is exposed to environmentally, for example an allergen, in which a humoral immune response is detrimental to the subject, for example results in an allergic

0033566.061899

reaction. Inhibition of a humoral immune response in this situation would be therapeutically beneficial to the subject.

I. GP39 ANTAGONISTS

According to the methods of the invention, a gp39 antagonist is administered to a subject to interfere with the interaction of gp39 on T cells with a gp39 ligand on B cells. A gp39 antagonist is defined as a molecule which interferes with this interaction. The gp39 antagonist can be an antibody directed against gp39 (e.g., a monoclonal antibody against gp39), fragments or derivative of an antibody directed against gp39 (e.g., Fab or F(ab)'2 fragments, chimeric antibodies or humanized antibodies), soluble forms of a gp39 ligand (e.g., soluble CD40), soluble forms of a fusion protein of a gp39 ligand (e.g., soluble CD40Ig), or pharmaceutical agents which disrupt the gp39-CD40 interaction.

A. Antibodies

A mammal, (e.g., a mouse, hamster, or rabbit) can be immunized with an immunogenic form of gp39 protein or protein fragment (e.g., peptide fragment) which elicits an antibody response in the mammal. A cell which expresses gp39 on its surface can also be used as the immunogen. Alternative immunogens include purified gp39 protein or protein fragments. gp39 can be purified from a gp39-expressing cell by standard purification techniques; gp39 cDNA (Armitage et al., *Nature*, 357:80-82 (1992); Lederman et al., *J. Exp. Med.*, 175:1091-1101 (1992); Hollenbaugh et al., *EMBO J.*, 11:4313-4319 (1992)) can be expressed in a host cell, e.g. bacteria or a mammalian cell line, and gp39 protein purified. gp39 peptides can be synthesized based upon the amino acid sequence of gp39 (Armitage et al., *Nature*, 357:80-82 (1992); Lederman et al., *J. Exp. Med.*, 175:1091-1101 (1992); Hollenbaugh et al., *EMBO J.*, 11:4313-4319 (1992)). Techniques for conferring immunogenicity on a protein include conjugation to carriers or other techniques well known in the art. For example, the protein can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard

0933566 061899

[illegible][illegible][illegible]

	1970	1980	1990	2000	2010	2020	2030	2040	2050	2060	2070	2080	2090	2100	2110	2120	2130	2140	2150	2160	2170	2180	2190	2200	2210	2220	2230	2240	2250	2260	2270	2280	2290	2300	2310	2320	2330	2340	2350	2360	2370	2380	2390	2400	2410	2420	2430	2440	2450	2460	2470	2480	2490	2500	2510	2520	2530	2540	2550	2560	2570	2580	2590	2600	2610	2620	2630	2640	2650	2660	2670	2680	2690	2700	2710	2720	2730	2740	2750	2760	2770	2780	2790	2800	2810	2820	2830	2840	2850	2860	2870	2880	2890	2900	2910	2920	2930	2940	2950	2960	2970	2980	2990	3000	3010	3020	3030	3040	3050	3060	3070	3080	3090	3100	3110	3120	3130	3140	3150	3160	3170	3180	3190	3200	3210	3220	3230	3240	3250	3260	3270	3280	3290	3300	3310	3320	3330	3340	3350	3360	3370	3380	3390	3400	3410	3420	3430	3440	3450	3460	3470	3480	3490	3500	3510	3520	3530	3540	3550	3560	3570	3580	3590	3600	3610	3620	3630	3640	3650	3660	3670	3680	3690	3700	3710	3720	3730	3740	3750	3760	3770	3780	3790	3800	3810	3820	3830	3840	3850	3860	3870	3880	3890	3900	3910	3920	3930	3940	3950	3960	3970	3980	3990	4000	4010	4020	4030	4040	4050	4060	4070	4080	4090	4100	4110	4120	4130	4140	4150	4160	4170	4180	4190	4200	4210	4220	4230	4240	4250	4260	4270	4280	4290	4300	4310	4320	4330	4340	4350	4360	4370	4380	4390	4400	4410	4420	4430	4440	4450	4460	4470	4480	4490	4500	4510	4520	4530	4540	4550	4560	4570	4580	4590	4600	4610	4620	4630	4640	4650	4660	4670	4680	4690	4700	4710	4720	4730	4740	4750	4760	4770	4780	4790	4800	4810	4820	4830	4840	4850	4860	4870	4880	4890	4900	4910	4920	4930	4940	4950	4960	4970	4980	4990	5000	5010	5020	5030	5040	5050	5060	5070	5080	5090	5100	5110	5120	5130	5140	5150	5160	5170	5180	5190	5200	5210	5220	5230	5240	5250	5260	5270	5280	5290	5300	5310	5320	5330	5340	5350	5360	5370	5380	5390	5400	5410	5420	5430	5440	5450	5460	5470	5480	5490	5500	5510	5520	5530	5540	5550	5560	5570	5580	5590	5600	5610	5620	5630	5640	5650	5660	5670	5680	5690	5700	5710	5720	5730	5740	5750	5760	5770	5780	5790	5800	5810	5820	5830	5840	5850	5860	5870	5880	5890	5900	5910	5920	5930	5940	5950	5960	5970	5980	5990	6000	6010	6020	6030	6040	6050	6060	6070	6080	6090	6100	6110	6120	6130	6140	6150	6160	6170	6180	6190	6200	6210	6220	6230	6240	6250	6260	6270	6280	6290	6300	6310	6320	6330	6340	6350	6360	6370	6380	6390	6400	6410	6420	6430	6440	6450	6460	6470	6480	6490	6
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	---

other species, with human constant regions. A variety of approaches for making chimeric antibodies have been described and can be used to make chimeric antibodies containing the immunoglobulin variable region which recognizes gp39. See, for example, Morrison et al., *Proc. Natl. Acad. Sci. U.S.A.* 81:6851 (1985); Takeda et al., *Nature* 314:452 (1985), Cabilly et al., U.S. Patent No. 4,816,567; Boss et al., U.S. Patent No. 4,816,397; Tanaguchi et al., European Patent Publication EP171496; European Patent Publication 0173494, United Kingdom Patent GB 2177096B. It is expected that such chimeric antibodies would be less immunogenic in a human subject than the corresponding non-chimeric antibody.

For human therapeutic purposes the monoclonal or chimeric antibodies specifically reactive with a gp39 protein or peptide can be further humanized by producing human constant region chimeras, in which parts of the variable regions, especially the conserved framework regions of the antigen-binding domain, are of human origin and only the hypervariable regions are of non-human origin. Such altered immunoglobulin molecules may be made by any of several techniques known in the art, (e.g., Teng et al., *Proc. Natl. Acad. Sci. U.S.A.*, 80:7308-7312 (1983); Kozbor et al., *Immunology Today*, 4:7279 (1983); Olsson et al., *Meth. Enzymol.*, 92:3-16 (1982)), and are preferably made according to the teachings of PCT Publication WO92/06193 or EP 0239400. Humanized antibodies can be commercially produced by, for example, Scotgen Limited, 2 Holly Road, Twickenham, Middlesex, Great Britain.

Another method of generating specific antibodies, or antibody fragments, reactive against a gp39 protein or peptide is to screen expression libraries encoding immunoglobulin genes, or portions thereof, expressed in bacteria with a gp39 protein or peptide. For example, complete Fab fragments, VH regions and Fv regions can be expressed in bacteria using phage expression libraries. See for example Ward et al., *Nature*, 341: 544-546: (1989); Huse et al., *Science*, 246: 1275-1281 (1989); and McCafferty et al., *Nature*, 348: 552-554 (1990). Screening such libraries with, for example, a gp39 peptide can identify immunoglobulin fragments reactive with gp39. Alternatively, the SCID-hu mouse developed by Genpharm can be used to produce antibodies, or fragments thereof.

0035686.061899

For suppression of humoral immune responses in a human subject, it is preferable to administer an antibody directed against human gp39. The following methodology was used to produce mouse anti-human gp39 monoclonal antibodies.

Balb/c mice were immunized with a soluble gp39 fusion protein, gp39-CD8, in Complete Freund's Adjuvant (CFA). Mice were subsequently challenged 6 weeks later with soluble gp39-CD8 in Incomplete Freund's Adjuvant (JFA). Soluble gp39-CD8 was given in soluble form 4 weeks after secondary immunization. Mice were then boosted with activated human peripheral blood lymphocytes 2 weeks later, followed by a final boost with soluble gp39-CD8 after an additional 2 weeks. Splenocytes were fused with the NS-1 fusion partner on day 4 after final immunization as per standard protocols.

Clones producing anti-human gp39 antibodies were selected based on a multiple screening process. Clones were initially screened by a plate binding assay using gp39-CD8. Positive clones were then screened against a control CD8 fusion protein, CD72-CD8. Clones which scored positive on the CD8-CD72 plate binding assay were eliminated. The remaining clones were subsequently screened on resting and 6 hour activated human peripheral blood lymphocytes (PBL) by flow cytometric analysis. Hybridomas staining activated, but not resting, PBL were considered positive. Finally, the remaining clones were tested for their ability to block the binding of CD40Ig to plate bound gp39.

Approximately 300 clones were initially screened against gp39-CD8 and CD72-CD8 in the plate binding assays. Of those clones, 30 were found to detect plate-bound gp39 and not CD8. These clones were subsequently screened for detection of gp39 on activated human PBL. Approximately 15 clones detected a molecule on activated PBL, but not resting cells. Specificity was further confirmed by determining the capacity of the clones to block CD40Ig detection of plate-bound gp39. 3 of 10 clones tested block CD40Ig binding in this assay. These clones were 3E4, 2II5 and 2II8. Such clones are preferred for use in the methods described herein. Clones which

00335686 061899
668190 98956660

In a preferred embodiment of the invention, the gp39 antagonist is a anti-mouse gp39 monoclonal antibody, MR1. The following method was used to produce the MR1 monoclonal antibody, and may be used to generate other antibodies directed toward gp39.

B. Soluble Ligands for gp39

Other gp39 antagonists which can be administered to suppress humoral immunity are soluble forms of a gp39 ligand. A monovalent soluble ligand of gp39 can bind gp39, thereby inhibiting the interaction of gp39 with CD40 on B cells. The term soluble indicates that the ligand is not permanently associated with a cell membrane. A soluble gp39 ligand can be prepared by chemical synthesis, or, preferably by recombinant DNA techniques. A preferred soluble gp39 ligand is soluble CD40. Alternatively, soluble gp39 ligand can be in the form of a fusion protein. Such a fusion protein comprises at least a portion of the gp39 ligand attached to a second molecule. For example, CD40 can be expressed as a fusion protein with immunoglobulin (CD40Ig). In one embodiment, a fusion protein is produced comprising amino acid residues of an extracellular domain portion of the

CD40 joined to amino acid residues of a sequence corresponding to the hinge, CH2 and CH3 regions of C γ 1 to form a CD40Ig fusion protein (see e.g., Linsley et al. (1991) *J. Exp. Med.* 1783:721-730; Capon et al. (1989) *Nature* 337, 525-531; and Capon U.S. 5,116,964). The fusion protein can be produced by chemical synthesis, or, preferably by recombinant DNA techniques based on the cDNA of CD40 (Stamenkovic et al., *EMBO J.*, 8:1403-1410 (1989)).

II. ANTIGENS AGAINST WHICH HUMORAL IMMUNITY IS SUPPRESSED

The invention is directed to suppressing humoral immunity against antigens which require contact-dependent helper functions delivered by Th cells. Antigens classically described as thymus-dependent (TD) antigens are encompassed by the invention. The necessity for contact-dependent "help" from Th cells can be due to the necessity for an interaction between gp39 on T cells and CD40 on B cells. As defined by the current invention, the term "TD antigen" is intended to encompass antigens which require a gp39-CD40 interaction between T cells and B cells for induction of a humoral immune response against the antigen. In general, protein antigens are TD antigens. Another form of TD antigen encompassed by the invention is a molecule, referred to as a hapten, linked to a protein. In this case, the protein acts as a carrier for inducing T cell help in order to induce humoral immune responses against the hapten.

The TD antigen of the invention can be administered in soluble form to a subject, e.g., injection of a soluble protein, or the TD antigen can be on the surface of a cell, e.g., a cell-surface protein. The TD antigen can be administered to a subject with a gp39 antagonist or a subject may be exposed to a TD antigen environmentally, for example an allergen. In preferred embodiments, the TD antigen is an agent administered to a subject for therapeutic purposes. This agent can be, for example, a therapeutic antibody or other form of therapeutic drug which is a TD antigen. Inhibiting a humoral immune response against, for instance, a therapeutic antibody, can prolong its efficacy *in vivo* by preventing clearance of the therapeutic antibody in a subject. Small molecules acting as therapeutic agents can also be target

003566 061899 668T90" 9895EE60

antigens against which a humoral response is suppressed if these molecules (functioning as haptens) are administered with a protein or other carrier that induces T cell helper function to activate B cells; suppressing humoral immunity against these therapeutic agents can likewise prolong their effectiveness.

The methods of the invention provide for suppression of humoral immunity against TD antigens while not affecting responses to thymus-independent type II (TI-2) antigens. TI-2 antigens include polysaccharides and lipids which can non-specifically activate B cells in a polyclonal manner. As defined by the current invention, the term "TI-2 antigen" is intended to encompass all antigens which do not require a gp39-CD40 interaction between T cells and B cells for induction of a humoral immune response against the antigen. The current invention provides a method for identifying whether an antigen is a TD antigen or a TI-2 antigen, as defined in the invention, by determining whether humoral immune responses to the antigen can be inhibited by a gp39 antagonist.

III. SUPPRESSION OF HUMORAL IMMUNITY

The invention pertains to methods of inhibiting a humoral immune response against a TD antigen. The humoral immune response can be a primary immune response, in the case of a first exposure to a TD antigen, or the response can be a secondary humoral immune response, in the case of reexposure to the antigen. Production of one or more isotypes of antibodies can be inhibited. For a primary humoral immune response, in which IgM is the predominant antibody produced, IgM production is predominantly suppressed. For secondary immune response, production of several different isotypes, including IgM, IgG and IgE can be suppressed.

The invention provides methods for prolonged suppression of humoral immunity against a TD antigen. As used herein, "prolonged suppression" means that suppression of antibody production against a TD antigen is maintained after administration of a gp39 antagonist *in vivo* has been terminated.

IV. ADMINISTRATION OF GP39 ANTAGONISTS

Humoral immune responses to a TD antigen can be inhibited according to the methods described herein by administration of a gp39 antagonist to a subject which is exposed to the TD antigen. In one embodiment, the gp39 antagonist is administered in conjunction with the TD antigen. The gp39 antagonist is preferably administered simultaneously with the TD antigen, but can be administered prior to administering the TD antigen or subsequent to the TD antigen, as long as the gp39 antagonist is administered before the TD antigen has induced B cell activation. In other embodiments, a subject is exposed to an antigen environmentally. In this case, a gp39 antagonist should be administered *in vivo* following exposure to the antigen, in close enough in time to prevent B cell activation.

The antagonists of the invention are administered to subjects in a biologically compatible form suitable for pharmaceutical administration *in vivo* to suppress humoral immune responses. By "biologically compatible form suitable for administration *in vivo*" is meant a form of the antagonist to be administered in which any toxic effects are outweighed by the therapeutic effects of the protein. The term subject is intended to include living organisms in which an immune response can be elicited, e.g., mammals. Examples of subjects include humans, dogs, cats, mice, rats, and transgenic species thereof. Administration of an antagonist which interferes with the interaction of gp39 and CD40 as described herein can be in any pharmacological form and a pharmaceutically acceptable carrier. Administration of a therapeutically active amount of the therapeutic compositions of the present invention is defined as an amount effective, at dosages and for periods of time necessary to achieve the desired result. For example, a therapeutically active amount of an antagonist which interferes with the interaction of gp39 and CD40 may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the antagonist to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

The active compound (e.g., antagonist) may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active compound may be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound.

To administer an antagonist which interferes with the interaction of gp39 and CD40 by other than parenteral administration, it may be necessary to coat the antagonist with, or co-administer the antagonist with, a material to prevent its inactivation. For example, an antagonist can be administered to an individual in an appropriate carrier or diluent, co-administered with enzyme inhibitors or in an appropriate carrier such as liposomes. Pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasylol. Liposomes include water-in-oil-in-water emulsions as well as conventional liposomes (Strejan et al., (1984) *J. Neuroimmunol* 7:27).

The active compound may also be administered parenterally or intraperitoneally. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. In all cases, the composition must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be

0923556 061899

achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, asorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating active compound (e.g., antagonist which interferes with the interaction of gp39 and CD40) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient (e.g., antagonist) plus any additional desired ingredient from a previously sterile-filtered solution thereof.

When the active compound is suitably protected, as described above, the protein may be orally administered, for example, with an inert diluent or an assimilable edible carrier. As used herein "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the therapeutic compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to

093500 061899

produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.

V. COADMINISTRATION OF GP39 ANTAGONISTS AND OTHER IMMUNOSUPPRESSIVE AGENTS

It has been shown that the interference by soluble CTLA-4 of CD28 triggering, a co-stimulatory molecule on T_H cells, also suppresses TD antibody responses (30) and blocks xenogeneic graft rejection (31). Similar to anti-gp39 administration, soluble CTLA-4 induced a state of prolonged immune suppression. Because anti-gp39 and CTLA-4 mediate their immunosuppressive effects at distinct stages of the humoral immune response, co-administration of these two immunosuppressive drugs may provide additive or synergistic immunosuppressive effects on immunity.

Allergic responses are mediated by IgE antibodies. The production of IgE responses requires the cytokine IL-4. Inhibition of IgE responses against a TD antigen may be more efficient by coadministration of a gp39 antagonist and an inhibitor of IL-4, for example an anti-IL-4 antibody.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references and published patent applications cited throughout this application are hereby incorporated by reference. The contents of a patent application filed on even date herewith in the name of Randolph J. Noelle et al. and entitled "Methods for Inducing Antigen-Specific T Cell Tolerance" is incorporated herein by reference.

The following methodology was used in the examples.

Materials and Methods

Animals. Female, 6-8 week old Balb/c mice (Jackson Laboratories, Bar Harbor, ME) were used for the *in vivo* experiments presented in this study.

Animals were maintained in the specific pathogen-free animal facility at Dartmouth Medical School.

Helper T cell clones (T_H1). D1.6, an I-A^d-restricted, rabbit Ig-specific T_H1 clone (21) was obtained from Dr. David Parker, University of Mass. at Worcester. In this paper, D1.6 will be referred to as T_H1.

Reagents and Antibodies. MR1, hamster anti-murine gp39 mAb (16) was purified by DEAE HPLC from ascites fluid. Hamster Ig (HIg), used as a control antibody, was purified similarly from hamster serum (Accurate Chemical and Scientific Corp., Westbury, NY). RG7/7.6.HL, a mouse anti-rat κ chain (strongly crossreactive with hamster κ chain) antibody, (RG7), (22) was conjugated with HRPO or FITC and used as a secondary reagent to detect MR1 and HIg. Affinity-purified Goat anti-mouse IgM, IgG₁, IgG_{2a}, IgG_{2b} and IgG₃ (Southern Biotechnology, Birmingham AL) were used as detection antibodies in the antigen specific ELISAs as well as in the total IgM and IgG₁ ELISAs. B1E3, (kindly provided by Dr. T. Waldschmidt, Univ. of Iowa) a monoclonal anti-murine IgE, was used as the detection antibody for the IgE anti-KLH ELISA. Chimeric-L6 (Chi-L6), a humanized IgG₁ specific for the tumor antigen L6 (23), was kindly provided by Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle WA. Anti-CD4, GK 1.5 (24) was prepared by HPLC purification of ascites fluid. Sheep red blood cells (SRBC) were purchased from Colorado Serum Co. (Denver, CO). Sea Plaque agarose for use in anti-SRBC plaque assay was obtained from FMC Corporation (Rockland MA). Baby rabbit complement was purchased from Cedarlane (Hornby, Ontario Canada). KLH, Keyhole limpet hemocyanin, (from *Megathura crenulata*) was purchased from Calbiochem (LaJolla, CA). Complete Freund's adjuvant (CFA) for immunizations was obtained from Sigma Chemical Co (St. Louis, MO). TNP-SRBC, TNP-KLH and TNP-BSA were prepared as previously described (25).

003306 061399
003306 061399

Immunizations for Generation of In Vivo Primary and Secondary Antibody Responses.

Primary Immune Responses. For eliciting primary antibody responses to SRBC or TNP-SRBC, mice were immunized with 200 μ l of 1% SRBC or TNP-SRBC suspension (i.v.). The IgM, anti-SRBC response was assayed 5d after administration of antigen using a modification of the Jerne plaque assay (26). IgM anti-TNP responses were measured by ELISA on day 6. Primary responses to the heterologous immunoglobulin Chi-L6 were generated by i.p. immunization of 100 μ g Chi-L6 on alum per mouse. The serum IgM anti-Chi-L6 antibody response was measured after 7d. Primary responses to TNP-Ficoll were generated by immunization with 25 μ g of TNP-Ficoll i.p. The IgM anti-TNP response was measured on day 6 by ELISA.

Secondary Immune Responses. For generation of secondary humoral responses to KLH, animals were immunized with KLH in CFA (50 μ g; i.p.). Mice were subsequently challenged with 10 μ g of soluble KLH (i.p.) three months later. The anti-KLH antibody response was measured on d7 from the serum of immune mice utilizing isotype specific ELISAs. Secondary antibody responses to Chi-L6 were generated by challenging Chi-L6 immune mice with 10 μ g soluble Chi-L6, i.p. The serum IgG₁ anti-Chi-L6 antibody response was measured after 7d.

Anti-gp39 Treatment. Sterile, HPLC-purified anti-gp39 (MR1) or HIg (as an antibody control) was administered (i.p.) on d0, d2, d4 post immunization or challenge as indicated for each experiment.

Antigen Specific ELISAs. The antigen specific IgM, IgG₁, IgG_{2a}, IgG_{2b}, IgG₃, and IgE antibody titers were determined using isotype specific ELISAs. Briefly, antigen, (1 mg/ml of KLH, Chi-L6, TNP₁₆-BSA, or TNP₂-BSA in PBS) was absorbed onto flexible polyvinyl microtiter dishes, overnight at 4°C. Plates were washed and blocked with PBS-1% FCS- sodium-azide. Diluted serum samples were incubated for 2 hours at 37°C. Samples were washed and the antigen specific antibody titers determined with one of the following alkaline-phosphatase conjugated detection antibodies: goat anti-mouse IgM, IgG₁, IgG_{2a}, IgG_{2b}, or IgG₃ (Southern Biotechnology,

09335686.061899

[illegible][illegible][illegible][illegible]

Adoptive Transfer of Helper T cells. Mice were immunized with SRBC (200 μ l of 1% SRBC, i.v.) and administered anti-gp39 or HIg (250 μ g on d0, d2, d4). On d7 the splenocytes from nonimmune or SRBC-immune mice were removed, erythrocyte depleted, washed and transferred (i.v., 50×10^6 /mouse) into irradiated recipients (600 rads) with or without 50×10^6 spleen cells from TNP-KLH primed (TNP-KLH-CFA, 50 μ g i.p.) mice as a source of immune B cells. At the time of transfer, mice were immunized with TNP-SRBC (200 μ l of 1% TNP-SRBC i.v.) Serum IgG1 anti-TNP titers were ascertained on d6 post-transfer.

EXAMPLE 1: Anti-gp39 Inhibits the Generation of Primary Antibody Responses to Erythrocyte Antigens

The impaired TD immunity observed in patients with HIM, as well as the potent inhibitory effects of anti-gp39 and CD40-Ig on T_h -dependent B cell activation *in vitro*, provided the basis for the study of the potential immunosuppressive effects of anti-gp39 on humoral-mediated immunity *in vivo*. To investigate the role of gp39-CD40 interactions in primary TD humoral immune responses, the effect of *in vivo* administration of anti-gp39 on the primary antibody response to sheep red blood cells (SRBC) was determined. Animals were immunized with SRBC and administered anti-gp39 mAb (or control HIg) over the course of 4d. On d5, the primary anti-SRBC antibody response of anti-gp39-treated, HIg-treated, and control mice was ascertained. The IgM anti-SRBC plaque-forming cell (PFC) response of mice that received a total of 1.5 mg of anti-gp39 (500 μ g/mouse on d0, d2 and d4) was reduced 99% when compared to the anti-SRBC PFC response from control or HIg-treated mice (Figure 1A). In addition, administration of as little as 300 μ g/mouse (100 μ g/mouse on d0, d2, and d4) of anti-gp39 reduced the anti-SRBC primary immune response by 66%. Results from these experiments demonstrate that anti-gp39 treatment ablates primary antibody responses *in vivo*.

The duration of the immunosuppressive effects of anti-gp39 on the primary humoral immune response to SRBC was subsequently examined. Mice immunized with SRBC were treated with anti-gp39 for 4d and assayed at various later time points for the capacity to mount a primary anti-SRBC

00335686 061899
668790" 98955660

response. In this set of experiments, all animals were immunized with SRBC on d0 and administered anti-gp39 or HIg on d0, d2, d4. The IgM anti-SRBC PFC response was measured for one group on d5. Additional SRBC-immune groups were challenged with SRBC on d7 or d14. Five days following the each antigenic challenge (d12 and d19, respectively), the IgM anti-SRBC PFC response was measured. The results of one such experiment are depicted in Figure 1B. As in Figure 1A, the primary anti-SRBC responses were inhibited 80-90% 5d after anti-gp39 administration was begun. In addition, the primary anti-SRBC responses 12d and 19d following anti-gp39 treatment were also inhibited >90%. These results demonstrate that brief anti-gp39 treatment results in prolonged inhibition of primary antibody responses.

EXAMPLE 2: Anti-gp39 Inhibits the Generation of Secondary Anti-KLH Antibody Responses

Experiments examining primary antibody responses suggest that gp39-CD40 interactions play a critical role in the initiation of primary humoral immunity. However, these experiments do not address the whether gp39-dependent CD40 signalling is required for the generation of secondary antibody responses. Therefore, the effects of anti-gp39 administration on the secondary immune response to soluble challenge with KLH was determined in KLH-immune mice.

Using schedules of anti-gp39 administration that reduced the primary anti-SRBC PFC response, experiments were designed to evaluate the effects of anti-gp39 treatment on the secondary antibody responses. In these experiments, KLH-immune mice (immunized 3 months prior with CFA and KLH) were challenged with soluble KLH (10 µg/mouse/i.v.). On the day of antigen challenge (d0), mice were also given 250 µg of anti-gp39 or HIg, followed by anti-gp39 or HIg on d2 and d4. At d7 (Fig. 2 panel A) and d14 (Fig. 2 panel B) following challenge with KLH, the mice were bled and the titers of IgM, IgG1, IgG2a, IgG2b, IgG3 and IgE anti-KLH antibodies were determined. The results demonstrate several points: 1) challenge with soluble KLH induced an enduring secondary immune response that persisted for up to 14d; 2) the administration of anti-gp39 significantly reduced the secondary anti-KLH response of the isotypes measured when compared to the

EXAMPLE 3: Anti-gp39 Inhibits the Generation of Antibody Responses to Heterologous Ig

Experiments depicted in Figure 1 demonstrate the immunosuppressive activity of anti-gp39 during a primary response to a strongly immunogenic particulate antigen, SRBC. The cellular nature of erythrocytes makes them unique in their capacity to elicit strong immune responses. Heterologous Ig molecules share this characteristic of being highly immunogenic, and therefore provide an additional model antigen system with which to examine the effects of anti-gp39 treatment on the generation of primary and secondary antibody responses. Animals were immunized with a heterologous Ig molecule, Chi-L6, a humanized mouse anti-tumor cell mAb, and treated with anti-gp39 or control HIg. After 7d, sera was collected and assayed for the production of IgM anti-Chi-L6 antibodies. In addition, mice were challenged with Chi-L6 14d after initial immunization and anti-gp39 treatment, and assayed for IgG1 anti-Chi-L6 antibody production on d21. Figure 3 depicts the results of one such experiment. The primary antibody response to Chi-L6 in mice treated with anti-gp39 is inhibited by > 90% when compared to HIg-treated mice. Moreover, the secondary, IgG1 response to Chi-L6 is similarly inhibited. These results demonstrate that anti-gp39 treatment ablates primary and secondary antibody responses to a second type of TD antigen, heterologous Ig, as effectively as it suppresses responses to erythrocyte and soluble protein antigens.

EXAMPLE 4: Anti-gp39 Does Not Inhibit the Generation of Primary Antibody Responses to the T-Independent Type II Antigen, TNP-Ficoll.

Although the previous experiments demonstrate that anti-gp39 effectively blocks the generation of primary and secondary antibody responses to TD antigens *in vivo*, it is unclear whether gp39-CD40 interactions play a role in the initiation of humoral responses to TI antigens. Data presented in the accompanying paper demonstrate that immunization with the TI-type II antigen, TNP-Ficoll, results in gp39 expression by T_h cells *in vivo*. In order to address whether gp39-CD40 interactions are necessary for the generation of antibody responses to this TI antigen, the affect of anti-gp39 treatment on mice immunized TNP-Ficoll, was assessed. Mice immunized with TNP-Ficoll or TNP-SRBC were treated with anti-gp39 or HIg and the IgM anti-TNP antibody response determined after 6 days. Figure 4A demonstrates that animals immunized with the TD antigen TNP-SRBC elicit significant anti-TNP serum antibody responses. As predicted from the previously described experiments, anti-gp39 treatment dramatically inhibits the primary anti-TNP response generated in these mice. In contract, mice immunized with TNP-Ficoll mount a higher titered anti-TNP antibody response (Figure 4B); however, treatment with anti-gp39 does not inhibit the antibody response to TNP-Ficoll. Results from these experiments demonstrate that, unlike responses to TD antigens, anti-gp39 does not block the generation of humoral responses to TNP-Ficoll, suggesting that responses to TI antigens may be gp39-independent.

EXAMPLE 5: Anti-gp39 Administration Does Not Functionally Delete SRBC-Specific T_h

From the previous experiments, it is known that anti-gp39 interferes with the development of TD humoral immunity; however, the mechanism by which anti-gp39 treatment suppresses humoral responses is not clear. Immune suppression by anti-gp39 could be mediated by: 1) the negative signalling of gp39-bearing T cells causing T_h anergy; 2) mAb-mediated cytotoxic deletion of anti-gp39 bearing CD4⁺ T cells; and/or 3) the blocking

of gp39 binding to CD40. A series of experiments were performed to gain insight into which of these mechanisms may be operative in the protracted immune suppression observed with anti-gp39 therapy. To explore the possibility that antigen-specific T_H were deleted or anergized by anti-gp39 therapy, antigen-specific T_H function from gp39-treated mice was measured by adoptive transfer. Briefly, mice were immunized with SRBC (to prime SRBC-specific T_H) and administered anti-gp39 or HIg (250 μ g/mouse on d0, d2, d4). After 7d, spleen cells from unimmunized mice or SRBC-immune spleen cells from HIg-treated or anti-gp39-treated mice were adoptively transferred into recipient mice with TNP-immune spleen cells as a source of TNP-primed B cells. Mice were simultaneously challenged with TNP-SRBC, and the IgG1 anti-TNP titer ascertained on d5. SRBC-primed T helper cells are required to elicit a secondary anti-TNP response in the recipient mice as demonstrated by the fact that recipients which received spleen cells from nonimmune donors produced substantially lower IgG1 anti-TNP compared to those mice which received spleen cells from SRBC-primed animals (Figure 5). More importantly, results of these experiments revealed that the SRBC helper activity from HIg-treated and anti-gp39-treated mice was similar, indicating that anti-gp39 treatment did not alter T_H function or block the priming of T_H . Moreover, antigen-responsive T_H were not deleted or anergized as a result of anti-gp39 treatment, as they provided helper-effector function upon transfer.

EXAMPLE 6: In Vivo Clearance of Hamster Anti-gp39.

Previous studies have established that anti-gp39 (MR1) blocks the binding of gp39 to CD40 (15) and thus support the hypothesis that the *in vivo* immunosuppressive effects of anti-gp39 are due to the blocking of gp39-CD40 interactions. Assuming this hypothesis correct, the long-term immune suppression observed with anti-gp39 administration requires the persistence of anti-gp39 in the host. To determine if anti-gp39 could be detected for the period of time that immune suppression was evident, the *in vivo* clearance rate of anti-gp39 from serum was determined. Mice were given a regime of antibody (3 x 250 μ g anti-gp39) over the course of 4d and assayed for the levels of serum anti-gp39 at 7d, 14d, and 21d after the initiation of antibody

administration. Western blot analysis for non-reduced MR1 (160 kd) indicated that intact, serum anti-gp39 could be detected for at least 21d after the initiation of antibody treatment (Figure 6A). The serum concentration of anti-gp39 in animals at 21d was approximately 5% (based on scanning densitometry), when compared to the signals derived from serum of animals analyzed 7d after initiation of antibody therapy.

Although it was determined that intact anti-gp39 was present in serum, it was also important to ascertain that the anti-gp39 was biologically active. Therefore, sera from mice which received 3 x 250 µg of anti-gp39 over the course of 4d were used to stain gp39-bearing T_h (Figure 6B). The level of serum anti-gp39 3d after the last injection (7d after initiation of antibody treatment) was set at 100%. Fourteen days after the initiation of antibody therapy, approximately 10-15% of the biologically active anti-gp39 mAb was detected in the serum. Twenty-one days post-initiation of therapy, 2-3% of anti-gp39 remained in the serum. Therefore, both the determination of intact gp39 by Western blotting and of biologically active anti-gp39 revealed that approximately 5% of the anti-gp39 was present 21d after beginning anti-gp39 therapy. These results demonstrate the half-life of anti-gp39 to be approximately 12d and offer evidence consistent with the hypothesis that prolonged suppression of humoral immune responses by anti-gp39 is due to persistent blocking of T_h function.

The present study demonstrates that *in vivo* administration of an anti-gp39 antibody which blocks gp39-CD40 interactions *in vitro*, results in profound inhibition of both primary and secondary humoral immune responses to TD antigens, but not TI-type II antigens. In addition, this study demonstrates that anti-gp39 treatment does not block the priming of antigen-primed T_h cells. Therefore, the gp39-CD40 ligand-receptor pair can be used as a target for the therapeutic manipulation of the humoral immune response.

To gain insight into how anti-gp39 was exerting its immunosuppressive effect on humoral immunity, the direct effects of anti-gp39 on T_h function were addressed. The data indicate that SRBC-immune T_h from anti-gp39-treated mice were fully capable of providing help upon adoptive transfer, suggesting that anti-gp39 treatment did not cause T_h

09335506.061999

deletion or anergy *in vivo*. These results led to the speculation that anti-gp39 mediates its immunosuppressive effects by blocking gp39 binding to CD40 and not by the inactivation of gp39-bearing T_h. In support of this hypothesis *in vitro* studies have established that anti-gp39 blocks the binding of CD40 to gp39 (16). Furthermore, biologically active anti-gp39 could be detected in serum for the period of time that immune suppression was apparent. Although only 5% of anti-gp39 was present in serum at a time when immune suppression was evident, it is possible that the local tissue concentrations of anti-gp39 in specific sites of secondary lymphoid organs is higher and clearance rates are slower than that of serum anti-gp39.

Treatment of mice with anti-gp39 inhibited the primary immune response to SRBC and heterologous Ig >90% for prolonged periods of time. Assuming that anti-gp39 is mediating the inhibition by blocking gp39 function, these data implicate gp39-CD40 interactions as essential in the development of primary immune responses to TD antigens. Immunohistochemical analysis establish that gp39 is induced as a consequence of immunization with TD antigens and may be of functional significance. The *in situ* studies of gp39 expression illustrate that the initial site of gp39-CD40 interactions during primary humoral immune responses is in the peripheral aspects of the periarteriolar lymphoid sheaths (PALS) and around the terminal arterioles (TA) of the spleen. It is at these sites that conjugates between gp39-expressing T_h and antigen-specific B cells were found juxtaposed, suggesting that the outer PALS is a major site of T cell-B cell interactions during primary humoral immune responses. Therefore, the PALS may be the site at which anti-gp39 interacts with gp39-expressing T_h cells to ultimately inhibit T-B interaction and subsequent Ig production.

Similar to primary responses, the secondary humoral immune response of mice primed to KLH in CFA was also shown to be inhibited by the administration of anti-gp39. Consistent with the reduction of anti-SRBC PFC by anti-gp39, reductions in serum antibodies titers to antigenic challenge were also observed. The serum titers of all anti-KLH Ig isotypes measured (IgM, IgG1, IgG2a, IgG2b, IgG3, and IgE) were reduced by the treatment of mice with anti-gp39. The effect of anti-gp39 administration was apparent for at least 14d after secondary challenge with antigen, establishing a persistent

003356 061899

immune suppression by anti-gp39. Anti-gp39-mediated immune suppression of secondary responses to KLH is not unique to KLH, since secondary immune responses to heterologous Ig and heterologous erythrocytes were also inhibited by anti-gp39 therapy. The anatomical distribution of gp39-expressing T_H was identical to that observed upon primary immunization, however, the frequency of gp39-expressing T_H in immune spleen was increased over that observed during primary immune responses. No gp39-expressing T_H were found in the germinal centers or follicles of immune spleen. Thus, it appears that B cells are triggered to respond to activated T_H cells in the PALS and TA of the spleen and later migrate to the follicles and germinal centers.

The focus of the present study was to demonstrate the potential use of anti-gp39 in the control of TD humoral immunity. Brief treatment regimes with anti-gp39 resulted in prolonged suppression, an attractive attribute of this therapeutic antibody. Of special interest may be the capacity of anti-gp39 to prevent primary and secondary humoral responses to other heterologous, therapeutic antibodies such as Chi-L6. This would permit the exposure of patients to repeated administrations of heterologous therapeutic antibodies.

The following references are referred to by number in the examples and detailed description of the invention:

1. Inaba K., M.D. Witmer, R.M. Steinman. 1984. Clustering of dendritic cells, helper T lymphocytes, and B cells during primary antibody responses in vitro. *J. Exp. Med.* 160:858.
2. Inaba K., R.M. Steinman. 1985. Protein-specific helper T-lymphocyte formation initiated by dendritic cells. *Science*. 229:475.
3. Noelle R.J., E.C. Snow. 1991. Cognate interactions of helper T cells and B cells. *Immunol. Tod.* 11:361.

4. Gordon J., M.J. Millsum, G.R. Guy, J.A. Ledbetter. 1987. Synergistic interaction between interleukin 4 and anti-Bp50 (CDw40) revealed in a novel B cell restimulation assay. *Eur. J. Immunol.* 17:1535.
5. Clark E.A., J.A. Ledbetter. 1986. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp 50. *Proc. Natl. Acad. Sci. USA.* 83:4494.
6. Stamenkovic I., E.A. Clark, B. Seed. 1989. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. *EMBO* . 8:1403.
7. Hollenbaugh D., L. Grosmaire, C.D. Kulas, N.J. Chalupny, R.J. Noelle, I. Stamenkovic, J.A. Ledbetter, A. Aruffo. 1992. The human T cell antigen p39, a member of the TNF gene family, is a ligand for the CD40 receptor: Expression of a soluble form of gp39 with B cell co-stimulatory activity. *EMBO*. 11:4313.
8. Armitage R.J., W.C. Fanslow, L. Strockbine, T.A. Sato, K.N. Clifford, B.M. Macduff, D.M. Anderson, S.D. Gimpel, T. Davis-Smith, C.R. Maliszewski, E.A. Clark, C.A. Smith, K.H. Grabstein, D. Cosman, M.K. Spriggs. 1992. Molecular and biological characterization of a murine ligand for CD40. *Nature*. 357:80.
9. Valle A., C.E. Zuber, T. Defrance, O. Djossou, R.M. De, J. Banchereau. 1989. Activation of human B lymphocytes through CD40 and interleukin 4. *Eur. J. Immunol.* 19:1463.
10. Gordon J., M.J. Millsum, R.L. Flores, S. Gillis. 1989. Regulation of resting and cycling human B lymphocytes via surface the accessory molecules interleukin-4, CD23 and CD40. *Immunology*. 68:526.
11. Jabara H.H., S.M. Fu, R.S. Geha, D. Vercelli. 1990. CD40 and IgE: synergism between anti-CD40 monoclonal antibody and interleukin 4 in the

005566-061890

induction of IgE synthesis by highly purified human B cells. *J. Exp. Med.* 172:1861.

12. Banchereau J., F. Rousset. 1991. Growing human B lymphocytes in the CD40 system. *Nature.* 353:678.

13. Armitage R.J., T.A. Sato, B.M. Macduff, K.N. Clifford, A.R. Alpert, C.A. Smith, W.C. Fanslow. 1992. Identification of a source of biologically active CD40 ligand. *Eur. J. Immunol.* 22:2071.

14. Lane P., A. Traunecker, S. Hubele, S. Inui, A. Lanzavecchia, D. Gray. 1992. Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes. *Eur. J. Immunol.* 22:2573.

15. Noelle R.J., J.A. Ledbetter, A. Aruffo. 1992. CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B cell activation. *Immunol. Tod.* 13:431.

16. Noelle R.J., M. Roy, D.M. Shepherd, I. Stamenkovic, J.A. Ledbetter, A. Aruffo. 1992. A novel ligand on activated T helper cells binds CD40 and transduces the signal for the cognate activation of B cells. *Proc. Natl. Acad. Sci. USA.* 89:6550.

17. Allen R.C., R.J. Armitage, M.E. Conley, H. Rosenblatt, N.A. Jenkins, N.G. Copeland, M.A. Bedell, S. Edelhoff, J. Disteche, D.K. Simoneaux, W.C. Fanslow, J. Belmont, M.K. Spriggs. 1993. CD40 ligand gene defects responsible for X-linked hyper-IgM Syndrome. *Science.* 259:990.

18. Aruffo A., M. Farrington, D. Hollenbaugh, Li X., A. Milatovich, S. Nonoyama, J. Bajorath, L.S. Grosmaire, R. Stenkamp, M. Neubauer, R.L. Roberts, R.J. Noelle, Ledbetter, U. J.A. Francke, H.D. Ochs. 1993. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. *Cell.* 72:291.

0035586 061899 663790 98955560

19. DiSanto J.P., J.Y. Bonnefoy, J.F. Gauchat, A. Fischer, G. de Saint Basile. 1993. CD40 ligand mutations in X- linked immunodeficiency with hyper- IgM. *Nature*. 361:541.
20. Korthauer U., D. Graf, H.W. Mages, F. Brieres, M. Padayachee, S. Malcolm, A.G. Ugazio, L.D. Notarangelo, R.L. Levinsky, A. KroczeK. 1993. Defective Expression of T- cell CD40 ligand causes X- linked immunodeficiency with hyper- IgM. *Nature*. 361:539.
21. Kurt-Jones E., S. Hamberg, J. Ohara, W.E. Paul, A.K. Abbas. 1987. Heterogeneity of helper/inducer T lymphocytes. I. Lymphokine production. *J. Exp. Med.* 166:1774.
22. Springer T.A., A. Bhattacharya, J.T. Cardoza, F. Sanchez-Madrid. 1982. Monoclonal antibodies specific for rat IgG1, IgG2a, and IgG2b subclasses, and kappa chain monotypic and allotypic determinants: reagents for use with rat monoclonal antibodies. *Hybrid*. 1:25.
23. Hellstrom I. 1986. Monoclonal mouse antibodies raised against human lung carcinoma. *Can. Res.* 46:3917.
24. Wilde D.B., P. Marrack, J. Kappler, D.P. Dialynas, F.W. Fitch. 1983. Evidence implicating L3T4 in class II MHC antigen reactivity; monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines. *J. Immunol.* 131:2178.
25. Snow E.C., R.J. Noelle. 1987. Thymus-dependent antigenic stimulation of hapten-specific B lymphocytes. *Immunol. Rev.* 99:173.
26. Jerne N.K. C. Henry, A. A. Nordin, H. Fuji, A. M. Koros, and I. Lefkovits. 1974. Plaque forming cells: Methodology and theory. *Transplant Rev.* 18:130.

27. Ochs H.D., R.J. Wedgewood. 1989. Disorders of the B cell system. *In* Immunologic disorders in infants and children, Third ed., E.R. Sreihm, ed. (Philadelphia: W. B. Saunders), pp. 226.
28. Notarangelo L.D., M. Duse, A.G. Ugazio. 1992. Immunodeficiency with hyper-IgM (HIM). *Immunodef. Rev.* 3:101.
29. Shizuru J.A., S.A. Alters, C.G. Fathman. 1992. Anti-CD4 monoclonal antibodies in therapy: Creation of nonclassical tolerance in the adult. *Immunol. Rev.* 129:103.
30. Linsley P.S., P.M. Wallace, J. Johnson, M.G. Gibson, J.L. Greene, J.A. Ledbetter, C. Singh, M.A. Tepper. 1992. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. *Science.* 257:792.
31. Lenschow D.J., Y. Zeng, J.R. Thistlethwaite, A. Montag, W. Brady, M.G. Gibson, P.S. Linsley, J.A. Bluestone. 1992. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. *Science.* 257:789.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

CLAIMS

1. A method for inhibiting a humoral immune response to a TD antigen *in vivo* comprising administering to a subject the TD antigen with an antagonist of a molecule on a Th cell which mediates contact-dependent helper effector function.
2. The method of claim 1 wherein the molecule on a Th cell which mediates contact-dependent helper effector function is gp39.
3. The method of claim 2 wherein the antagonist is an anti-gp39 antibody.
4. A method for inhibiting a humoral immune response to a TD antigen *in vivo* comprising administering to a subject the TD antigen with a gp39 antagonist.
5. The method of claim 4 wherein the humoral immune response is a primary humoral immune response.
6. The method of claim 4 wherein the humoral immune response is a secondary humoral immune response.
7. The method of claim 4 wherein the TD antigen is a protein.
8. The method of claim 4 wherein the TD antigen is an antibody.
9. The method of claim 4 wherein the TD antigen is on a cell surface.
10. The method of claim 4 wherein the gp39 antagonist is an anti-gp39 antibody.
11. The method of claim 10 wherein the anti-gp39 antibody is MR1.

12. The method of claim 10 wherein the anti-gp39 antibody is a chimeric monoclonal antibody.
13. The method of claim 10 wherein the anti-gp39 antibody is a humanized monoclonal antibody.
14. The method of claim 4 wherein the gp39 antagonist is a soluble form of a gp39 ligand.
15. The method of claim 14 wherein the gp39 ligand is CD40.
16. The method of claim 15 wherein CD40 is a fusion protein.
17. The method of claim 4 wherein humoral immune responses to TI-2 antigens are not inhibited.
18. A method for inhibiting an antigen specific IgE response to a TD antigen *in vivo* comprising administering to a subject exposed to the TD antigen a gp39 antagonist.
19. The method of claim 18 wherein the gp39 antagonist is an anti-gp39 antibody.
20. The method of claim 19 wherein the anti-gp39 antibody is MR1.
21. The method of claim 19 wherein the anti-gp39 antibody is a chimeric monoclonal antibody.
22. The method of claim 19 wherein the anti-gp39 antibody is a humanized monoclonal antibody.
23. The method of claim 18 wherein the gp39 antagonist is a soluble form of a gp39 ligand.

033500-061899

24. The method of claim 23 wherein the gp39 ligand is CD40.
25. The method of claim 24 wherein CD40 is a fusion protein.
26. A method for inhibiting a humoral immune response to a therapeutic agent *in vivo* comprising administering to a subject the therapeutic agent with a gp39 antagonist.
27. The method of claim 26 wherein the therapeutic agent is an antibody.
28. The method of claim 26 wherein the gp39 antagonist is an anti-gp39 antibody.
29. The method of claim 28 wherein the anti-gp39 antibody is MR1.
30. The method of claim 28 wherein the anti-gp39 antibody is a chimeric monoclonal antibody.
31. The method of claim 28 wherein the anti-gp39 antibody is a humanized monoclonal antibody.
32. The method of claim 26 wherein the gp39 antagonist is a soluble form of a gp39 ligand.
33. The method of claim 32 wherein the gp39 ligand is CD40.
34. The method of claim 33 wherein CD40 is a fusion protein.
35. A method for inhibiting a humoral immune response to an allergan *in vivo* comprising administering to a subject exposed to the allergan a gp39 antagonist.
36. The method of claim 35 further comprising administering an IL-4 inhibitor to the subject.

652190 9295550

37. The method of claim 36 wherein the IL-4 inhibitor is an anti-IL-4 antibody.
38. A method for prolonged suppression of a humoral immune response to a TD antigen *in vivo* comprising administering to a subject the TD antigen with a gp39 antagonist.
39. A method for inhibiting a humoral immune response to a TD antigen *in vivo* while preserving humoral immune responses to TI-2 antigens comprising administering to a subject the TD antigen with a gp39 antagonist.
40. A method for immunosuppressing function of activated Th cells induced by a TD antigen *in vivo* comprising administering to a subject the TD antigen with a gp39 antagonist.
41. The method of claim 59 wherein activated Th cells are not deleted.
42. The method of claim 59 wherein activated Th cells are not anergized.
43. A method for determining whether an antigen is a TD antigen or a TI-2 antigen, comprising:
- (a) administering to a subject the antigen to be tested with a gp39 antagonist;
 - (b) measuring humoral immune responses against the antigen;
and
 - (c) determining that the antigen is a TD antigen by an absence of humoral immune responses or determining that the antigen is a TI-2 antigen by a presence of humoral immune responses.

09335686 061899
PAT 90 9895560

Abstract

Methods of suppressing a humoral immune response to a thymus-dependent (TD) antigen are disclosed. The methods involve administering to a subject a TD antigen with an antagonist of a molecule which mediates contact-dependent helper effector functions. In a preferred embodiment, the antagonist is an antagonist of gp39. Primary and secondary humoral immune responses can be suppressed and suppression is prolonged.




FIG. 1A




FIG. 1B

Anti-KLH units

Isotype

Isotype	Group 1 (hatched)	Group 2 (white)
IgM	~90	~25
IgG1	~580	~5
IgG2a	~85	~5
IgG2b	~150	~5
IgG3	~40	~15
IgE	~25	~1

Isotype	Hatched Bar (Anti-KLH units)	White Bar (Anti-KLH units)
IgM	100	40
IgG1	390	80
IgG2a	100	20
IgG2b	100	10
IgG3	100	10
IgE	25	2

FIG. 2B




FIG. 3A




FIG. 3B




FIG. 4A




FIG. 4B




FIG. 5




FIG. 6A




FIG. 6B

Declaration, Petition and Power of Attorney For Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

METHODS OF PROLONGED SUPPRESSION OF HUMORAL IMMUNITY
the specification of which

(check one)

is attached hereto.

X was filed on June 7, 1995 as

X Application Serial No. 08/475,873

and was amended on _____
(if applicable)

I do not know and do not believe that the subject matter of this application was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to the date of this application, and that said subject matter has not been patented or made the subject of an issued inventor's certificate in any country foreign to the United States on an application filed by me or my legal representatives or assigns more than twelve months prior to the date of this application; that I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application, that no application for patent or inventor's certificate on the subject matter of this application has been filed by me or my representatives or assigns in any country foreign to the United States, except those identified below, and that I have reviewed and understand the contents of the specification, including the claims as amended by any amendment referred to herein.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Check one:

☐ no such applications have been filed.

☒ such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

Country	Application Number	Date of Filing (month,day,year)	Priority Claimed Under 35 USC 119
PCT	PCT/US94/09872	02 September 1994	<input checked="" type="checkbox"/> Yes No <input type="checkbox"/>
			<input type="checkbox"/> Yes No <input type="checkbox"/>
			<input type="checkbox"/> Yes No <input type="checkbox"/>
			<input type="checkbox"/> Yes No <input type="checkbox"/>
			<input type="checkbox"/> Yes No <input type="checkbox"/>

ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application. As to subject matter of this application which is common to my earlier United States application, if any, described below, I do not believe that the same was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to said earlier application, or in public use or on sale in the United States more than one year prior to said earlier application, that the said common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of said earlier application in any country foreign to the United States on an application, filed by me or my legal representatives or assigns more than twelve months prior to said application and that no application for patent or inventor's certificate on said subject matter has been filed by me or my representatives or assigns in any country foreign to the United States except those identified herein.

<u>08/115,990</u> (Application Serial No.)	<u>September 2, 1993</u> (Filing Date)	<u>pending</u> (Status) (patented,pending,aband.)
<u> </u> (Application Serial No.)	<u> </u> (Filing Date)	<u> </u> (Status) (patented,pending,aband.)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

John A. Lahive, Jr.	Reg. No. 19,788	Jeremiah Lynch	Reg. No. 17,425
W. Hugo Liepmann	Reg. No. 20,407	Amy E. Mandragouras	Reg. No. 36,207
James E. Cockfield	Reg. No. 19,162	Elizabeth A. Hanley	Reg. No. 33,505
Thomas V. Smurzynski	Reg. No. 24,798	Matthew P. Vincent	Reg. No. 36,709
Ralph A. Loren	Reg. No. 29,325	Paul Louis Myers	Reg. No. 35,965
Thomas J. Engellenner	Reg. No. 28,711	Beth E. Arnold	Reg. No. 35,430
William C. Geary III	Reg. No. 31,359	Anthony A. Laurentano	Reg. No. 38,220
Giulio A. DeConti, Jr.	Reg. No. 31,503	Jane E. Remillard	Reg. No. 38,872
Michael I. Falkoff	Reg. No. 30,833	Jean M. Silveri	Reg. No. 39,030
Ann Lamport Hammitte	Reg. No. 34,858	Mark A. Kurisko	Reg. No. 38,944
John V. Bianco	Reg. No. 36,748	Edward J. Kelly	Reg. No. 38,936

Send Correspondence to:

Lahive & Cockfield, 60 State Street, Boston, MA 02109

Direct Telephone Calls to: (name and telephone number)

Amy E. Mandragouras, (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor Randolph J. Noelle	
Inventor's signature	Date
Residence Rural Route 3, Box 257, Cornish, New Hampshire 03745	
Citizenship United States of America	
Post Office Address (if different) same as above	

Teresa M. Foy

Lerean M. Fay

Date _____

10/2/95

Residence

Residence 590 Galer St #116 Seattle, WA 98109 JF
3-13 Meadowbrook Village, Lebanon, New Hampshire 03756

Citizenship

United States of America

Post Office Address (if different)

same as above

Table 1. Demographic characteristics of the study population	
Age (years)	50.0 ± 10.0
Gender	
Male	50.0%
Female	50.0%
Education (years)	12.0 ± 2.0
Marital status	
Married	70.0%
Single	30.0%
Occupation	
Professional	40.0%
Managerial	30.0%
Technical	20.0%
Service	10.0%
Unemployed	0.0%
Income (USD/month)	1,500.0 ± 500.0
Health status	
Good	80.0%
Fair	10.0%
Poor	10.0%

Socioeconomic characteristics		Health status		Health care utilization		Health care costs	
White	Black	White	Black	White	Black	White	Black
Age, years							
18-24	18-24	18-24	18-24	18-24	18-24	18-24	18-24
25-34	25-34	25-34	25-34	25-34	25-34	25-34	25-34
35-44	35-44	35-44	35-44	35-44	35-44	35-44	35-44
45-54	45-54	45-54	45-54	45-54	45-54	45-54	45-54
55-64	55-64	55-64	55-64	55-64	55-64	55-64	55-64
65-74	65-74	65-74	65-74	65-74	65-74	65-74	65-74
75-84	75-84	75-84	75-84	75-84	75-84	75-84	75-84
85+	85+	85+	85+	85+	85+	85+	85+
Sex							
Male	Male	Male	Male	Male	Male	Male	Male
Female	Female	Female	Female	Female	Female	Female	Female
Marital status							
Married	Married	Married	Married	Married	Married	Married	Married
Single	Single	Single	Single	Single	Single	Single	Single
Widowed	Widowed	Widowed	Widowed	Widowed	Widowed	Widowed	Widowed
Divorced	Divorced	Divorced	Divorced	Divorced	Divorced	Divorced	Divorced
Education							
Less than high school	Less than high school	Less than high school	Less than high school	Less than high school	Less than high school	Less than high school	Less than high school
High school graduate	High school graduate	High school graduate	High school graduate	High school graduate	High school graduate	High school graduate	High school graduate
Some college	Some college	Some college	Some college	Some college	Some college	Some college	Some college
College graduate	College graduate	College graduate	College graduate	College graduate	College graduate	College graduate	College graduate
Income							
Less than \$10,000	Less than \$10,000	Less than \$10,000	Less than \$10,000	Less than \$10,000	Less than \$10,000	Less than \$10,000	Less than \$10,000
\$10,000-\$19,999	\$10,000-\$19,999	\$10,000-\$19,999	\$10,000-\$19,999	\$10,000-\$19,999	\$10,000-\$19,999	\$10,000-\$19,999	\$10,000-\$19,999
\$20,000-\$29,999	\$20,000-\$29,999	\$20,000-\$29,999	\$20,000-\$29,999	\$20,000-\$29,999	\$20,000-\$29,999	\$20,000-\$29,999	\$20,000-\$29,999
\$30,000-\$39,999	\$30,000-\$39,999	\$30,000-\$39,999	\$30,000-\$39,999	\$30,000-\$39,999	\$30,000-\$39,999	\$30,000-\$39,999	\$30,000-\$39,999
\$40,000-\$49,999	\$40,000-\$49,999	\$40,000-\$49,999	\$40,000-\$49,999	\$40,000-\$49,999	\$40,000-\$49,999	\$40,000-\$49,999	\$40,000-\$49,999
\$50,000-\$59,999	\$50,000-\$59,999	\$50,000-\$59,999	\$50,000-\$59,999	\$50,000-\$59,999	\$50,000-\$59,999	\$50,000-\$59,999	\$50,000-\$59,999
\$60,000-\$69,999	\$60,000-\$69,999	\$60,000-\$69,999	\$60,000-\$69,999	\$60,000-\$69,999	\$60,000-\$69,999	\$60,000-\$69,999	\$60,000-\$69,999
\$70,000-\$79,999	\$70,000-\$79,999	\$70,000-\$79,999	\$70,000-\$79,999	\$70,000-\$79,999	\$70,000-\$79,999	\$70,000-\$79,999	\$70,000-\$79,999
\$80,000-\$89,999	\$80,000-\$89,999	\$80,000-\$89,999	\$80,000-\$89,999	\$80,000-\$89,999	\$80,000-\$89,999	\$80,000-\$89,999	\$80,000-\$89,999
\$90,000-\$99,999	\$90,000-\$99,999	\$90,000-\$99,999	\$90,000-\$99,999	\$90,000-\$99,999	\$90,000-\$99,999	\$90,000-\$99,999	\$90,000-\$99,999
\$100,000+	\$100,000+	\$100,000+	\$100,000+	\$100,000+	\$100,000+	\$100,000+	\$100,000+
Health status							
Excellent	Excellent	Excellent	Excellent	Excellent	Excellent	Excellent	Excellent
Very good	Very good	Very good	Very good	Very good	Very good	Very good	Very good
Good	Good	Good	Good	Good	Good	Good	Good
Fair	Fair	Fair	Fair	Fair	Fair	Fair	Fair
Poor	Poor	Poor	Poor	Poor	Poor	Poor	Poor
Health care utilization							
Physician visits	Physician visits	Physician visits	Physician visits	Physician visits	Physician visits	Physician visits	Physician visits
0-4	0-4	0-4	0-4	0-4	0-4	0-4	0-4

Attorney's
Docket
Number DCI-073CN

Declaration, Petition and Power of Attorney For Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

METHODS OF PROLONGED SUPPRESSION OF HUMORAL IMMUNITY
the specification of which

(check one)

is attached hereto.

X was filed on June 7, 1995 as

X Application Serial No. 08/475,873

and was amended on _____
(if applicable)

I do not know and do not believe that the subject matter of this application was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to the date of this application, and that said subject matter has not been patented or made the subject of an issued inventor's certificate in any country foreign to the United States on an application filed by me or my legal representatives or assigns more than twelve months prior to the date of this application; that I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application, that no application for patent or inventor's certificate on the subject matter of this application has been filed by me or my representatives or assigns in any country foreign to the United States, except those identified below, and that I have reviewed and understand the contents of the specification, including the claims as amended by any amendment referred to herein.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Check one:

☐ no such applications have been filed.

☒ such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

Country	Application Number	Date of Filing (month,day,year)	Priority Claimed Under 35 USC 119
PCT	PCT/US94/09872	02 September 1994	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/>
			<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/>
			<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/>
			<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/>
			<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/>

ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application. As to subject matter of this application which is common to my earlier United States application, if any, described below, I do not believe that the same was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to said earlier application, or in public use or on sale in the United States more than one year prior to said earlier application, that the said common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of said earlier application in any country foreign to the United States on an application, filed by me or my legal representatives or assigns more than twelve months prior to said application and that no application for patent or inventor's certificate on said subject matter has been filed by me or my representatives or assigns in any country foreign to the United States except those identified herein.

<u>08/115,990</u>	<u>September 2, 1993</u>	<u>pending</u>
(Application Serial No.)	(Filing Date)	(Status)
		(patented,pending,aband.)
<u> </u>	<u> </u>	<u> </u>
(Application Serial No.)	(Filing Date)	(Status)
		(patented,pending,aband.)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

John A. Lahive, Jr.	Reg. No. 19,788	Jeremiah Lynch	Reg. No. 17,425
W. Hugo Liepmann	Reg. No. 20,407	Amy E. Mandragouras	Reg. No. 36,207
James E. Cockfield	Reg. No. 19,162	Elizabeth A. Hanley	Reg. No. 33,505
Thomas V. Smurzynski	Reg. No. 24,798	Matthew P. Vincent	Reg. No. 36,709
Ralph A. Loren	Reg. No. 29,325	Paul Louis Myers	Reg. No. 35,965
Thomas J. Engellenner	Reg. No. 28,711	Beth E. Arnold	Reg. No. 35,430
William C. Geary III	Reg. No. 31,359	Anthony A. Laurentano	Reg. No. 38,220
Giulio A. DeConti, Jr.	Reg. No. 31,503	Jane E. Remillard	Reg. No. 38,872
Michael I. Falkoff	Reg. No. 30,833	Jean M. Silveri	Reg. No. 39,030
Ann Lamport Hammitte	Reg. No. 34,858	Mark A. Kurisko	Reg. No. 38,944
John V. Bianco	Reg. No. 36,748	Edward J. Kelly	Reg. No. 38,936

Send Correspondence to:


Lahive & Cockfield, 60 State Street, Boston, MA 02109

Direct Telephone Calls to: (name and telephone number)

Amy E. Mandragouras, (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor	
Randolph J. Noelle	
Inventor's signature	Date
	10/20/95
Residence	
Rural Route 3, Box 257, Cornish, New Hampshire 03745	
Citizenship	
United States of America	
Post Office Address (if different)	
same as above	